|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Catalytic synthesis of acetals and ketals with H3PW12O40/PAn显示文摘A new environmental friendly catalyst H3PW12O40/PAn was prepared and identified by means of FT-IR,XRD,and TG/DTA.The optimum conditions have been found;that is,the mass ratio of PAn to H3PW12O40 is 1:1.5,the volume of methanol is 20 mL,and the reflux reaction time is 3 h.The structural identity of Keggin units is preserved after the incorporation into polyaniline matrix.Catalytic activities of H3PW12O40/PAn in synthesizing 2-methyl-2-ethoxycarbonylmethyl-1,3-dioxolane,2,4-dimethyl-2-ethoxycarbonylmethyl-1,3-dioxolane,cyclohexanone ethylene ketal,cyclohexanone 1,2-propanediol ketal,butanone ethylene ketal,butanone 1,2-propanediol ketal,2-phenyl-1,3-dioxolane,4-methyl-2-phenyl-1,3-dioxolane,2-propyl-1,3-dioxolane,and 4-methyl-2-propyl-1,3-dioxolane were reported.It has been demon-strated that H3PW12O40/PAn is an excellent catalyst.Various factors concerned in these reactions were investigated.The optimum conditions are as follows:the molar ratio of aldehyde/ketone to glycol(r) is 1:1.5,the mass ratio of the catalyst used to the reactants is 0.6%,and the reaction time is 1.0 h.Under these conditions,the yield is as follows:2-methyl-2-ethoxycarbonylmethyl-1,3-dioxolane,69.0%;2,4-dimethyl-2-ethoxycarbonylmethyl-1,3-dioxolane,79.5%;cyclohexanone ethylene ketal,78.9%;cyclohexanone 1,2-propanediol ketal,85.3%;butanone ethylene ketal,56.9%;butanone 1,2-propanediol ketal,78.1%;2-phenyl-1,3-dioxolane,76.3%;4-methyl-2-phenyl-1,3-dioxolane,94.2%;2-propyl-1,3-dioxolane,70.7%;and 4-methyl-2-propyl-1,3-dioxolane,79.2%. | YANG Shuijin ZHANG Yijun DU Xinxian Philippe G. Merle | 2008 | Rare Metals2008，27，1： | 11 |
| 2 | Combination therapy for advanced hepatocellular carcinoma:do we see the light at the end of the tunnel?显示文摘Importance:Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma(HCC),and consistently it is the hotspot in clinical studies.Objective:To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies.Evidence Review:We searched PubMed,MEDLINE,Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC.Findings:Several clinical issues are worth reconsidering,such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems,the translation of surrogate endpoint objective response rate(ORR)benefits into overall survival(OS)benefits,and whether conversion surgery contributes to initial expectations of long-term survival or not.New concepts in novel immunotherapy and targeted therapy in combination with loco-regional therapies may improve overall survival for HCC.Conclusions and Relevance for Reviews:Comprehensive understanding of the mechanism of immunotherapy and targeted therapy contributes to better prognosis of advanced HCC and more explorative combination therapies are needed. | Ti Zhang Philippe Merle Huaqi Wang Haitao Zhao Masatoshi Kudo | 2021 | Hepatobiliary Surgery and Nutrition2021，10，2： | 7 |
| 3 | Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs显示文摘 | Floriane Pez Ana?s Lopez Miran Kim Jack R. Wands Claude Caron de Fromentel Philippe Merle | 2013 | Journal of Hepatology2013，，： | 3 |
| 4 | Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma cells显示文摘 | Miran Kim Han Chu Lee Orkhontuya Tsedensodnom Rochelle Hartley Young-Suk Lim Eunsil Yu Philippe Merle Jack R. Wands | 2008 | Journal of Hepatology2008，，5： | 2 |
| 5 | Developmental origins of adult diseases and neurotoxicity: Epidemiological and experimental studies显示文摘 | Donald A. Fox Philippe Grandjean Didima de Groot Merle G. Paule | 2011 | Neurotoxicology2011，，4： | 1 |
| 6 | Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs显示文摘 | Floriane Pez Ana?s Lopez Miran Kim Jack R. Wands Claude Caron de Fromentel Philippe Merle | 2013 | Journal of Hepatology2013，，： | 1 |
| 7 | Catalytic synthesis of acetals and ketals with H3PW6Mo6O40/TiO2显示文摘 | YANG Shui-jin TONG Wen-long Philippe G. Merle | 2007 | Journal of Chemistry and Chemical Engineering2007，1，1： | 1 |
| 8 | Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma显示文摘 | Philippe Merle Suzanne de la Monte Miran Kim Marc Herrmann Shinji Tanaka Annette Von Dem Bussche Michael C. Kew Christian Trepo Jack R. Wands | 2004 | Gastroenterology2004，，4： | 1 |
| 9 | The Lateral Supramalleolar Flap: Experience With 41 Flaps显示文摘 | Philippe Voche Michel Merle Jean-David Stussi | 2005 | Annals of Plastic Surgery2005，，1： | 1 |
| 10 | Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies—mature results of the French Phase II RTF-1 trial显示文摘 | Fran?oise Mornex Nicolas Girard Christophe Beziat Abdul Kubas Mustapha Khodri Christian Trepo Philippe Merle | 2006 | International Journal of Radiation Oncology Biology Physics2006，，4： | 1 |
| 11 | High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology显示文摘 | Isabelle Chemin Fabien Zoulim Philippe Merle Ahmed Arkhis Michèle Chevallier Alan Kay Lucyna Cova Philippe Chevallier Bernard Mandrand Christian Trépo | 2001 | Journal of Hepatology2001，，3： | 1 |
| 12 | Increase of doxorubicin sensitivity by doxorubicin- loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo 显示文摘 | LUC BARRAUD PHILIPPE MERLE EMILIENNE SOMA | 2005 | Journal of Hepatology2005，42，： | 1 |
| 13 | Polyaniline Supported 12-Tungstosilicic Acid as the Catalyst for Acetals and Ketals Synthesis显示文摘A novel environmental friendly catalyst, H4SiW12O40/PAn was prepared and identified by FT-IR, XRD and TG/DTA. The optimal synthetic protocol was a PAn to H4SiW12O40 mass ratio of 1∶1, a 20 mL of methanol and a reaction time of 2 h at reflux. It was used in catalytic synthesis of ten important ketals and acetals with a high catalytic activity. With an aldehyde/ketone to glycol molar ratio of 1∶1.5 and a 1 wt% catalyst loading, the yields of ketals and acetals could reach 60.0%-93.8 % after 1 h. | 杨永金 PHILIPPE G Merle | 2009 | Journal of Wuhan University of Technology(Materials Science)2009，24，3： | 1 |
| 14 | Comparison and analysis of the efficacy of drug therapy for liver cancer显示文摘Hepatocellular carcinoma(HCC)is a poor prognosis tumor when not accessible to potentially curative treatments such as surgical resection,thermal ablations or liver transplantation.Systemic cytotoxic chemotherapies have shown inconsistent clinical benefit.In 2007,sorafenib,a tyrosine kinase inhibitor(TKI),was the first systemic therapy able to significantly improve the outcome of HCC patients non-eligible for curative or loco-regional therapies,despite a modest tolerance and low tumor objective response rate(ORR).Among the newer TKIs approved after 2017,lenvatinib was the first to show a striking ORR and demonstrate non-inferiority vs.sorafenib in the first-line setting.Furthermore,phase 3 trials showed the benefit of other TKIs,regorafenib and cabozantinib,and the anti-angiogenic ramucirumab monoclonal antibody,in systemic second-line therapy.Immune checkpoint inhibitors targeting PD1,achieved striking tumor shrinkage in some patients in monotherapy,seeming to be associated with exciting outcomes.Unfortunately,this occurred in too few patients to improve the median overall survival.More recently,the combination of anti-angiogenic drugs targeting the liver microenvironment with PD-1/PD-L1 inhibitors,such as the combination of bevacizumab and atezolizumab,proved to be substantially effective in phase 3,and other combinations of PD-1/PD-L1 and CTLA-4 inhibitors or TKIs have raised a lot of hopes for the systemic treatment of HCC. | Philippe Merle Miroslava Subic | 2020 | Hepatoma Research2020，6，9： | 0 |
| 15 | Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma显示文摘The Expert Consensus on the management of lenvatinib tolerance in patients with hepatocellular carcinoma(HCC)was published(1).There,the authors discussed how possibly lenvatinib-related adverse events could be managed in aim to ensure continued lenvatinib therapy at the highest possible dose,and as a result to gain optimal benefit on survival of patients.In this editorial,the place of lenvatinib in HCC therapeutic strategies as well as its tolerance are reviewed and discussed. | Philippe Merle | 2023 | Hepatobiliary Surgery and Nutrition2023，12，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员